John R. Moore - 06 Sep 2022 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
General Counsel
Signature
/s/ John R. Moore
Issuer symbol
EWTX
Transactions as of
06 Sep 2022
Net transactions value
-$42,469
Form type
4
Filing time
08 Sep 2022, 16:16:41 UTC
Previous filing
10 Aug 2022
Next filing
05 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $9,129 +4,730 +158% $1.93 7,730 06 Sep 2022 Direct
transaction EWTX Common Stock Sale $25,756 -2,379 -31% $10.83 5,351 06 Sep 2022 Direct F1, F2
transaction EWTX Common Stock Sale $25,842 -2,351 -44% $10.99 3,000 06 Sep 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -4,730 -3.6% $0.000000 127,727 06 Sep 2022 Common Stock 4,730 $1.93 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.93 to $10.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $10.93 to $11.08, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 1/48th of the shares subject to the option vest monthly beginning on January 16, 2021, subject to Reporting Person continuing as a service provider through each vest date.